Elite Pharmaceuticals Reports Positive Topline Results from a Pivotal Bioequivalence Study
14 août 2018 07h48 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and...
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
31 mai 2017 07h30 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 31, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) announced today the issuance of European Patent No. 1615623 titled...
Elite Pharmaceuticals’ SequestOx™ Study Results Expected in July
25 mai 2017 07h00 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 25, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), today announced that top-line results for its reformulated SequestOx™ study are...
Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss 3rd Quarter 2017 Financial Results on February 13, 2017
07 févr. 2017 08h00 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent...
Elite Announces U.S. FDA Priority Review Designation for SequestOx™ NDA
17 mars 2016 07h00 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., March 17, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today announced that the New Drug Application (NDA) for SequestOXTM...
Elite Pharmaceuticals, Inc. Reports Strong Growth for Second Quarter of Fiscal Year 2016
09 nov. 2015 16h37 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), announced results for the quarter ended September 30, 2015, the second...
Elite Pharmaceuticals, Inc. to Host Conference Call and Webcast to Discuss 1st Quarter 2016 Financial Results on August 11, 2015
06 août 2015 08h00 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent...
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
16 juin 2015 10h33 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 16, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today the issuance of U.S. Patent No. 9,056,054 entitled...
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
22 avr. 2014 07h41 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., April 22, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today the issuance of U.S. Patent No. 8,703,186 titled...
Elite Pharmaceuticals Expands Abuse Deterrent Technology Patent Portfolio Internationally
10 mars 2014 07h46 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., March 10, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the expansion of intellectual property protection surrounding...